Nexera Medical's Surgical N95 Respirator Mask Features Embedded Antibacterial Performance
Sciessent LLC, creator of ionic silver-based antimicrobial brands Agion® and Agion Active, announces the U.S. release of the Nexera Medical SpectraShieldTM model 9500 Surgical Respirator Mask using Foss Manufacturings FOSSHIELD® fibers treated with Agion antimicrobial technology. The mask recently received FDA 510(k) and NIOSH clearance, making it the first surgical respirator mask with embedded antibacterial performance to achieve FDA clearance in the United States.
"Considered the model for the next generation respirator mask, the SpectraShield 9500 surgical respirator is equivalent to a N95 (NIOSH rating),"Â says Paul Sallarulo, CEO of Nexera Medical. "The SpectraShield 9500 surgical respirator mask begins to eliminate certain strains of bacteria immediately on contact. This is the first mask treated with both AgIon and FOSSHIELD technology to receive FDA and NIOSH approval, and were excited to introduce it to the U.S. market."
Sciessent's customized Agion branded antimicrobial solutions incorporate silver ions in a zeolite carrier. The silver ions exchange with other positive ions (often sodium) from the moisture in the environment, effecting a release of silver "on demand." Depending on the microorganism, Agion antimicrobial technology has been shown to initially reduce microbial populate ions within minutes to hours while maintaining optimal performance for years. FOSSHIELD® incorporates Agion antimicrobial technology in a fiber system to deliver effective protection from microbes for the life of the product. The fiber can be blended into almost any fabric from cotton to nylon without changing its characteristics.
"Independent testing in the United States and Europe has shown the masks ability to kill 99.99 percent of tested bacteria on the surface of the mask within an hour including Methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes and Haemophilus influenza," says Paul Ford, CEO of Sciessent. "Sciessent has been steadily expanding our Agion technology into the medical device market, and were proud to partner on this innovative product with Foss and Nexera."
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
